Table 4.

Randomized trials evaluating the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients receiving peritoneal dialysis

AuthorYearNCharacteristicsDesignInterventionFollow-Up, moPrimary OutcomeOverall EffectDetails
Li et al. (53)200360Patients on PD with residual kidney functionOpen-labelRamipril (5 mg/d) versus no treatment12Rate of decline in residual GFR or complete anuriaBetterRamipril was superior to no treatment in reducing the incidence of complete anuria (HR, 58%; 95% CI, 36% to 94%)
Suzuki et al. (55)200324Patients on PD with LV hypertrophyDouble-blindValsartan (160 mg/d) versus placebo12Change in LV mass indexBetterCompared with placebo, valsartan therapy caused a greater regression of LV mass index (145±5 versus 121±4 g/m2; P<0.05)
Suzuki et al. (56)200434Patients on PD with hypertension and residual kidney functionOpen-labelValsartan (40–80 mg/d) versus other therapy not including ACEIs/ARBs24Rate of decline in residual GFRBetterValsartan retarded the loss of residual kidney function during follow-up (3.2±0.3 versus 4.3±0.7 ml/min per 1.73 m2), despite the absence of significant between-group difference in mean follow-up BP levels
Shigenaga et al. (54)200945Patients on PD with hypertensionOpen-labelCandesartan (16 mg/d) or valsartan (160 mg/d) or other therapy not including ACEIs/ARBs6Change in LV mass index and baPWVBetterDespite the absence of significant between-group difference in change of 24-h ambulatory BP, ARBs were superior to control therapy in causing regression of LV mass index and baPWV
  • PD, peritoneal dialysis; HR, hazard ratio; 95% CI, 95% confidence interval; LV, left ventricular; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; baPWV, brachial-ankle pulse wave velocity.